-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32

Benzinga·09/18/2026 13:16:42
Listen to the news
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.